Call for breast cancer drug price reduction

April 23, 2014 1:15 pm

Campaigners are calling on pharmaceutical company Roche to cut the price of a pioneering new breast cancer treatment amid indications the NHS drugs watchdog is set to reject its use on the service on cost grounds. NICE said the £90,000 cost of trastuzumab emtansine is not justifiable. Sir Andrew Dillon, NICE Chief Executive, said: “We had hoped that Roche would have recognised the challenge the NHS faces in managing the adoption of expensive new treatments by reducing the cost of Kadcyla to the NHS.”

Yahoo News.

Contact us

We would be delighted to hear from you. If you would like to get in touch with us, please contact us on 020 7463 0690 or use the form below.

We look forward to hearing from you.

For media enquiries, please contact Chris Rogers on 020 7793 2536 / 07720 054189, or email Chris.Rogers@whitehouseconsulting.co.uk.

Contact us via email

The Whitehouse Consultancy
305 The Metal Box Factory
30 Great Guildford Street
London SE1 0HS

Get directions
  • ace centre
  • Pancreatic Cancer UK
  • Pancreatic Cancer UK
  • Team GB
  • Lilian Baylis Technology School

Sign up for the latest news

  • * Donates required fields
  • This field is for validation purposes and should be left unchanged.

Contact us

  • * Denotes Required fields
  • This field is for validation purposes and should be left unchanged.